As of Beijing time The data is from a third-party organization and is only for reference.
For actual information, please refer to:www.eastmoney.com
Address: 470 Wildwood Ave, Woburn, MA 01801 (America)
Tel: +1(626)986-9880
Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK
Tel: 0044 7790 816 954
Email: marketing@medicilon.com
Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)
Postcode: 201299
Tel: +86 (21) 5859-1500 (main line)
Fax: +86 (21) 5859-6369
© 2023 Shanghai Medicilon Inc. All rights reserved Shanghai ICP No.10216606-3
Shanghai Public Network Security File No. 31011502018888 | Website Map
Business Inquiry
Global:
Email:marketing@medicilon.com
+1(626)986-9880(U.S.)
0044 7790 816 954 (Europe)
China:
Email: marketing@medicilon.com.cn
Tel: +86 (21) 5859-1500
The RG001 tablet is a new SHP2 allosteric inhibitor independently developed by Ringene using structural biology and drug metabolism-oriented drug design methods. Medicilon provided a range of preclinical services for the development of RG001 tablets, from drug target identification to IND filing, preparing them for clinical trials. These services included drug discovery, pharmaceutical research, and pre-clinical research (drug efficacy and safety evaluations).
ABM Therapeutics has been collaborating with Medicilon since 2016. During this partnership, Medicilon’s FTE team assisted ABM Therapeutics in discovering the clinical candidate compound (PCC) ABM-1310, which is currently undergoing simultaneous clinical trials in China and the United States.
MindRank, an AI pharmaceutical company, collaborated with Medicilon’s FTE services to combine AI design with laboratory confirmation effectively. In a short-term, cost-effective and high-efficient mode of operation, Medicilon successfully completed the collaborative project with high quality, earning the "2021 Excellent Team Award" from the customer.